Agarose Bead Technologies S.L. of Torrejón de Aroz at MEDICA 2022 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

Company news

Date

Topic

15 Sep 2022

Facilitating biopharmaceutical products time to market

Agarose Bead Technologies works with strategic partners like Repligen, a worldwide leader in prepacked columns, to facilitate biopharmaceutical products' time to market.

As the pharmaceutical industry becomes increasingly focused on biologics, having a robust purification process is key to delivering high-quality drug products.

The manufacturing of biologics is complex and depends on multiple factors such as the type of molecule and their impurities. Since each molecule is unique, designing a purification strategy is important for the project's success.

Agarose Bead Technologies (ABT) owns a proprietary agarose-based bead technology that develops a wide range of agarose resins that are used in chromatographic purification of biomolecules including proteins, antibodies, enzymes, and oligonucleotides, among others.

ABT is extremely committed to supporting the production of life-saving biotherapeutics and diagnostic tools. For this reason, relying on strategic partners like Repligen, a leader in prepacked columns, is crucial for our customers in the bioprocess industry. Recently, our General Manager, Carolina Egea, visited the impressive new Repligen manufacturing plant in Europe, located in Breda (The Netherlands), and took a nice photo next to one of the largest columns in the OPUS line, the OPUS 80R column, packed with 150L of our DEAE Rapid Run Ion Exchange resin.

Our continuous manufacturing capacity with improved scalability has speeded the time to market and met our commitment to satisfying the global demand of the biopharmaceutical industry. Additionally, with our recent manufacturing capacities expansion, and the implementation of new process analytical tools (PAT), we have improved the robustness of our processes, accelerated our scale-up to commercial production, and increase the efficient use of our resources.

In this way, drug manufacturers are provided with a reliable resin supply, on-time delivery, and consistent batch-to-batch quality purification resin to develop cost-effective biologic treatments for patients. That´s our satisfaction!

More Less

15 Sep 2022

Moving toward a new generation: new website and refreshed corporate image

Following our commitment to continuous innovation, we are pleased to announce our refreshed corporate image, as well as the launch of our new website.
In the new corporate image, a daring and minimalist design was used, which allows greater weight to be given to the brand values and reinforces the position as a dynamic and innovative company.

Likewise, the new company website is part of the ongoing evolution of ABT’s brand. The website features a modern design, improved functionality, and easy access to essential information, which offers an improved and pleasant user experience not only from a computer but also from a mobile device.

As a leading manufacturer of agarose resins, it’s important for us to provide content and information regarding our solutions, product features, and services to our current and prospective clients for their biologics manufacturing processes. Therefore, we will be bringing you up-to-date company information, and announcements, and sharing our knowledge and expertise in the bioprocessing field.

Our company is being transformed inside-out, with a solid corporate image that represents what it is today and what it will become in the future.

The expansion of our facilities, which will be completed by the end of 2022, will triple our production capacity to meet the global demand for agarose resins. With this upgrade, the company will be able to continuously manufacture and deliver an uninterrupted supply of high-quality agarose resins that develops and implements cost-effective, robust, and scalable production processes that support novel therapies worldwide including the mRNA-based Covid-19 vaccines.

We constantly work on ABT´s improvement to receive the trust and satisfaction of our customers.

More Less

Please log in

You must be logged in to use matchmaking